ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO
ADARx Pharmaceuticals raised $446.3 million in an upsized IPO, with shares opening 30% above the offering price on its Nasdaq debut. The San Diego-based late-stage gene therapy developer sold 26.3 million shares at the top of its marketed range. Founded in 2019, ADARx is among the latest biotech firms to capitalize on a resurgent public market.
The Atomic take
A nearly half-billion-dollar raise gives a company only six years old the runway to push its late-stage programs through pricey clinical trials without returning to investors on unfavorable terms. The 30% pop suggests appetite for RNA-focused developers is genuinely returning after a long biotech funding drought. Watch whether ADARx converts this cash into clinical readouts that justify the valuation, and whether the strong open pulls other San Diego and RNA-editing peers off the IPO sidelines.
Read the full story at Reuters →Know where humanity is headed.
Five forces, one investment thesis a day. Free, every weekday morning.
Get The Atomic Five